海尔生物
(688139)
| 流通市值：105.65亿 | | | 总市值：105.65亿 |
| 流通股本：3.16亿 | | | 总股本：3.16亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,963,966,298.13 | 1,296,472,460.72 | 652,078,594.24 | 2,328,672,376.01 |
| 营业收入 | 1,963,966,298.13 | 1,296,472,460.72 | 652,078,594.24 | 2,328,672,376.01 |
| 二、营业总成本 | 1,769,770,351.94 | 1,168,979,905.85 | 581,544,373.93 | 2,111,350,181.83 |
| 营业成本 | 1,037,369,849.9 | 685,462,902.24 | 342,016,271.67 | 1,239,105,142.69 |
| 税金及附加 | 17,031,504.42 | 10,980,541.94 | 5,976,918.91 | 22,653,316.45 |
| 销售费用 | 310,273,080.07 | 206,805,718.71 | 98,873,526.27 | 359,420,983.07 |
| 管理费用 | 145,341,250.33 | 95,535,365.3 | 48,191,207.24 | 192,799,698.62 |
| 研发费用 | 265,318,084.74 | 172,497,422.42 | 83,989,527.35 | 323,249,127.18 |
| 财务费用 | -5,563,417.52 | -2,302,044.76 | 2,496,922.49 | -25,878,086.18 |
| 其中:利息费用 | 2,828,528.36 | 1,825,535.7 | 883,959.2 | 3,909,387.58 |
| 其中:利息收入 | 23,381,386.82 | 16,396,216.38 | 8,762,595.23 | 35,370,669.84 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,586,154.89 | 2,224,070.28 | 496,729.71 | -494,110.38 |
| 加:投资收益 | 20,526,094.91 | 5,829,691.33 | 2,606,333.76 | 27,308,983.33 |
| 资产处置收益 | -60,872.64 | -102,532.28 | 88.5 | 632,148.71 |
| 资产减值损失(新) | -4,230,178.23 | -2,239,082.03 | 206,036.98 | -8,507,764.46 |
| 信用减值损失(新) | -2,199,792.65 | 963,879.07 | -6,844,353.25 | -12,795,863.25 |
| 其他收益 | 25,784,282.07 | 20,924,068.54 | 16,933,387.63 | 42,877,805.34 |
| 四、营业利润 | 235,601,634.54 | 155,092,649.78 | 83,932,443.64 | 266,343,393.47 |
| 加:营业外收入 | 3,029,886.45 | 2,183,527.9 | 1,235,935.33 | 2,064,888.6 |
| 减:营业外支出 | 983,324.7 | 811,741.82 | 561,951.32 | 3,648,309.24 |
| 五、利润总额 | 237,648,196.29 | 156,464,435.86 | 84,606,427.65 | 264,759,972.83 |
| 减:所得税费用 | 11,518,950.09 | 7,548,899.06 | 4,617,102.32 | 9,627,692.26 |
| 六、净利润 | 226,129,246.2 | 148,915,536.8 | 79,989,325.33 | 255,132,280.57 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 226,129,246.2 | 148,915,536.8 | 79,989,325.33 | 255,132,280.57 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 219,709,230.07 | 147,414,556.88 | 79,460,846.19 | 250,730,796.6 |
| 少数股东损益 | 6,420,016.13 | 1,500,979.92 | 528,479.14 | 4,401,483.97 |
| 扣除非经常损益后的净利润 | 198,205,181.4 | 137,547,657.29 | 70,673,678.49 | 219,650,111.67 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.7 | 0.47 | 0.25 | 0.8 |
| (二)稀释每股收益 | 0.7 | 0.47 | 0.25 | 0.8 |
| 八、其他综合收益 | -4,601,274.6 | -4,460,748.4 | -9,068.24 | 10,148,619.24 |
| 归属于母公司股东的其他综合收益 | -4,601,274.6 | -4,460,748.4 | -9,068.24 | 10,148,619.24 |
| 九、综合收益总额 | 221,527,971.6 | 144,454,788.4 | 79,980,257.09 | 265,280,899.81 |
| 归属于母公司股东的综合收益总额 | 215,107,955.47 | 142,953,808.48 | 79,451,777.95 | 260,879,415.84 |
| 归属于少数股东的综合收益总额 | 6,420,016.13 | 1,500,979.92 | 528,479.14 | 4,401,483.97 |
| 公告日期 | 2026-10-23 | 2026-08-20 | 2026-04-30 | 2026-03-28 |
| 审计意见(境内) | | | | 标准无保留意见 |